https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00angilma1https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngangilma12024-08-15 14:46:382024-08-15 14:46:38Negative impact of the IRA on patient access to innovative treatments
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00angilma1https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngangilma12024-08-15 14:46:382024-08-15 14:46:38Negative impact of the IRA on patient access to innovative treatments
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00angilma1https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngangilma12024-08-15 14:36:122024-08-15 14:36:12Novartis statement on Maximum Fair Price for Entresto
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00angilma1https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngangilma12024-08-15 14:36:122024-08-15 14:36:12Novartis statement on Maximum Fair Price for Entresto
